{
    "nct_id": "NCT04205630",
    "official_title": "A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy",
    "inclusion_criteria": "* Females with histologically confirmed recurrent, advanced or metastatic endometrial carcinoma\n* Eligible patients should have progressed on or after first line platinum-based chemotherapy for advanced/metastatic endometrial cancer. Patients who have had two or more lines of chemotherapy for advanced/metastatic disease are not eligible, taking into account the following:\n\n  * Patients may have received up to one additional line of chemotherapy if given in the neoadjuvant or adjuvant setting. If such treatment was completed less than 6 months prior to the current tumor recurrence or progression it is to be considered first-line treatment;\n  * No more than one line of non-cytotoxic systemic cancer therapy (such as immunotherapy, trastuzumab or protein kinase inhibitors) is allowed.\n* HER2 tumor expression defined as a 1+, 2+ or 3+ score on IHC or positive by ISH\n* At least one measurable cancer lesion as defined by the Response Evaluation Criteria for Solid Tumours (RECIST version 1.1);\n* Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2;\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current or previous use of a prohibited medication as listed in the protocol;\n* History of infusion-related reactions and/or hypersensitivity to trastuzumab;\n* History of keratitis;\n* Severe, uncontrolled systemic disease at screening;\n* Left Ventricular Ejection Fraction (LVEF) < 50%, or a history of clinically significant decrease in LVEF during previous treatment with trastuzumab;\n* History of clinically significant cardiovascular disease;\n* Symptomatic brain metastases, brain metastases requiring steroids to manage symptoms, or treatment for brain metastases within 8 weeks prior to randomization;\n* History or presence of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.",
    "miscellaneous_criteria": "Main"
}